Deals Of The Week: Merck KGaA/Symphogen, Valeant/Medicis, Medivir/Novadex
Executive Summary
Achillion brought in nearly $42 million in its third large fundraising over the past 24 months, but the virology-focused biotech may become an increasingly sought acquisition target as other hepatitis C candidates face hurdles or are shelved entirely.
You may also be interested in...
Valeant Continues Buying Spree With $2.6B Acquisition Of Medicis
The specialty pharma adds to its dermatology portfolio with a proposed acquisition of Scottsdale, Ariz.-based Medicis.
Merck KGaA Changes Manager Incentives, But Stays Mum On Job Losses
Germany's Merck KGaA implements share-based incentive scheme for top management and vows to improve financial transparency, while discussing cost-savings with employees.
High-Premium Buyouts Continue In Hepatitis C Space; Are Idenix And Achillion Next?
Bristol’s $2.5 billion tender for Inhibitex left many industry observers waiting to see what HCV players will do with only two independent pure-play HCV biotechs left. Idenix is eager to get its mid-stage nucleotide free of an FDA partial clinical hold, while Achillion says it has the assets to go it alone in the HCV competition.